Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
Become a Member | Sign in
Home>News>This Article

Crown Bioscience to Showcase Progression in Human Surrogate Trials

Published: Wednesday, May 21, 2014
Last Updated: Wednesday, May 21, 2014
Bookmark and Share
HuTrialTM demonstrates commitment to furthering preclinical understanding in order to improve personal care and increase patient recovery rates.

Crown Bioscience, Inc. will showcase their human surrogate trial platform at the 50th Annual ASCO Conference, taking place in Chicago, US, between 30th May and 3rd June. The HuTrialTM platform enables drug discovery and development companies to optimize their screening processes to ensure that only the most effective candidates are accelerated through to the clinic and onto improving patient care.

The most significant limitation to the development of new treatments in oncology is undoubtedly cost prohibition, as the attrition of a drug in the final stages of clinical trials carries significant financial implications for drug development. The HuTrial substitutes Phase-II trials at reduced cost, providing the opportunity for early decision making regarding drug candidate progression and significantly decreasing the risk of promoting ineffective therapeutics through the later stages of clinical testing.

The HuTrialTM platform substantially reduces the time and cost of phase-II trials and when used to identify patient biomarkers, it can effectively predict the clinical response of a prospective candidate before undergoing rigorous clinical testing. By evaluating all prospective treatments, surrogate trials can improve the success rate with which effective therapeutics reach the clinic and help reduce the chances of patients experiencing harmful or unpleasant side effects. HuTrials are conducted using Crown’s HuPrime® patient derived xenografts (PDX), where primary tumor cells are extracted directly from a patient and transplanted into surrogate, in most cases immunodeficient mice. As the cancer develops, prospective treatments can be administered to the surrogate host and the efficacy of prospective drug candidates can be observed and evaluated.

Jean-Pierre Wery, the President of Crown Bioscience comments; “At Crown Bioscience we are committed to improving the decision making process involved in submitting drug candidates for phase II and III clinical trials. As the most significant factor affecting the advancement of drug development is the cost of drug attrition in the later stages of clinical trials, it is important that we ensure that our clients do not waste resources on ineffective treatments. If we can assist them in identifying promising candidates early on, we can improve the rate at which effective new treatments are delivered into the clinic to improve patient outcomes. The HuTrialTM platform has the potential to help alleviate the socio-economic burden cancer has on the healthcare industry and assist in the global effort to convert cancer from a terminal condition to a chronic disease.”

The acclaimed ASCO Annual Meeting is attended by more than 25,000 oncology professionals, across a broad range of specialties. The itinerary includes workshops, education sessions, discussions, symposia and poster presentations to highlight clinical issues and frontline research and discovery. By bringing together individuals at the forefront of their respective fields, ASCO endeavors to unite the international oncological community with a view to sharing expertise, exploring new ideas, and further developing clinical and research techniques.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Crown Bioscience Passes 1000 Model Mark in PDX Collection for Oncology Drug Discovery
Size of collection allows for more informed preclinical decision making on prospective drug candidates.
Wednesday, April 23, 2014
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
World’s First Therapeutic Venom Database
Open-source library describes nearly 43,000 effects on the human body.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Potential Persistent Tuberculosis Treatment
Researchers have discovered several first-in-class compounds that target hidden TB infections by attacking a critical process the bacteria use to survive in the hostile environment of the lungs.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
The Do’s and Don’ts of SPR Experiments
Surface Plasmon Resonance (SPR) is a technique that is becoming more widely used, particularly by anyone who wants to obtain accurate on (association) and off (dissociation) rates for biomolecular binding.
Long-Sought Protein Sensor for the ‘Sixth Sense’ Discovered
In a study led by scientists from The Scripps Research Institute (TSRI)the sensor protein for propioception has been identified.
New Anti-Malarial Drug Screening Model
University of South Florida researchers demonstrate novel chemogenomic profiling to identify drug targets for the most lethal strain of malaria.
Shedding Light on “Dark” Cellular Receptors
UNC and UCSF labs create a new research tool to find homes for two orphan cell-surface receptors, a crucial step toward finding better therapeutics and causes of drug side effects.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos